Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

The effect of FBI CODIS Core STR Loci expansion on familial DNA database searching.

Karantzali E, Rosmaraki P, Kotsakis A, Le Roux-Le Pajolec MG, Fitsialos G.

Forensic Sci Int Genet. 2019 Nov;43:102129. doi: 10.1016/j.fsigen.2019.07.008. Epub 2019 Jul 27.

PMID:
31476659
2.

Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.

Messaritakis I, Nikolaou M, Koinis F, Politaki E, Koutsopoulos A, Lagoudaki E, Vetsika EK, Georgoulias V, Kotsakis A.

Lung Cancer. 2019 Sep;135:33-39. doi: 10.1016/j.lungcan.2019.06.025. Epub 2019 Jun 28.

PMID:
31447000
3.

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.

Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, Samantas E, Barlesi F, Roch B, Guillou A, Daurès JP.

PLoS One. 2019 Aug 20;14(8):e0220988. doi: 10.1371/journal.pone.0220988. eCollection 2019.

4.

4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.

Fortis SP, Kotsakis A, Le Tourneau C, Tsitsilonis OE, Georgoulias V, Baxevanis CN.

Cancer Immunol Immunother. 2019 Aug;68(8):1391-1400. doi: 10.1007/s00262-019-02364-2. Epub 2019 Jul 15. No abstract available.

PMID:
31309256
5.

CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?

Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK.

Ther Adv Med Oncol. 2019 Jun 12;11:1758835919853193. doi: 10.1177/1758835919853193. eCollection 2019.

6.

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.

Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V.

Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3.

PMID:
31203498
7.

Observing Severe Drought Influences on Ozone Air Pollution in California.

Demetillo MAG, Anderson JF, Geddes JA, Yang X, Najacht EY, Herrera SA, Kabasares KM, Kotsakis AE, Lerdau MT, Pusede SE.

Environ Sci Technol. 2019 May 7;53(9):4695-4706. doi: 10.1021/acs.est.8b04852. Epub 2019 Apr 10.

PMID:
30968688
8.

Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.

Economopoulou P, Kotoula V, Koliou GA, Papadopoulou K, Christodoulou C, Pentheroudakis G, Lazaridis G, Arapantoni-Dadioti P, Koutras A, Bafaloukos D, Papakostas P, Patsea H, Pavlakis K, Pectasides D, Kotsakis A, Razis E, Aravantinos G, Samantas E, Kalogeras KT, Economopoulos T, Psyrri A, Fountzilas G.

Transl Oncol. 2019 May;12(5):739-748. doi: 10.1016/j.tranon.2019.02.010. Epub 2019 Mar 14.

9.

The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Pistamaltzian NF, Georgoulias V, Kotsakis A.

Expert Rev Respir Med. 2019 May;13(5):435-447. doi: 10.1080/17476348.2019.1593828. Epub 2019 Mar 22.

PMID:
30869543
10.

Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.

Syrios J, Kouroussis C, Kotsakis A, Kentepozidis N, Kontopodis E, Kalbakis K, Vardakis N, Hatzidaki D, Polyzos A, Georgoulias V; GU Working Group of the Hellenic Oncology Research Group (HORG).

Minerva Ginecol. 2019 Jun;71(3):182-190. doi: 10.23736/S0026-4784.19.04249-7. Epub 2019 Feb 6.

PMID:
30727721
11.

Supraventricular tachycardia with QRS and cycle length alternans. What is the diagnosis?

Varvarousis D, Polytarchou K, Margos P, Psychari SN, Paravolidakis K, Tsoukalas D, Kotsakis A.

Hellenic J Cardiol. 2019 Jan 23. pii: S1109-9666(18)30526-8. doi: 10.1016/j.hjc.2019.01.006. [Epub ahead of print] No abstract available.

12.
13.

Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.

Kotoula V, Tsakiri K, Koliou GA, Lazaridis G, Papadopoulou K, Giannoulatou E, Tikas I, Christodoulou C, Chatzopoulos K, Bobos M, Pentheroudakis G, Tsolaki E, Batistatou A, Kotsakis A, Koutras A, Linardou H, Razis E, Res E, Pectasides D, Fountzilas G.

Clin Breast Cancer. 2019 Apr;19(2):113-125.e4. doi: 10.1016/j.clbc.2018.10.014. Epub 2018 Nov 5.

PMID:
30545790
14.

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V.

Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.

15.

Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).

Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group.

J Geriatr Oncol. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23.

PMID:
30366852
16.

Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.

Messaritakis I, Nikolaou M, Politaki E, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulia N, Georgoulias V, Kotsakis A.

Lung Cancer. 2018 Oct;124:270-278. doi: 10.1016/j.lungcan.2018.08.021. Epub 2018 Aug 27.

PMID:
30268472
17.

Opposite relations of epicardial adipose tissue to left atrial size in paroxysmal and permanent atrial fibrillation.

Psychari SN, Tsoukalas D, Varvarousis D, Papaspyropoulos A, Gkika E, Kotsakis A, Paraskevaidis IA, Iliodromitis EK.

SAGE Open Med. 2018 Sep 17;6:2050312118799908. doi: 10.1177/2050312118799908. eCollection 2018.

18.

Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.

Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V.

Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775. doi: 10.1007/s00280-018-3666-9. Epub 2018 Aug 9.

PMID:
30094617
19.

Biomarkers of Myocardial Injury and Inflammation after Permanent Pacemaker Implantation: The Lead Fixation Type Effect.

Varvarousis D, Goulas N, Polytarchou K, Psychari SN, Paravolidakis K, Konstantinidou A, Tsoukalas D, Vlad D, Bouki K, Kotsakis A.

J Atr Fibrillation. 2018 Apr 30;10(6):1798. doi: 10.4022/jafib.1798. eCollection 2018 Apr.

20.

Small cell carcinoma of the stomach: A report of two cases and a review of the literature.

Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N.

Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10.

21.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

PMID:
29767677
22.

Cartilage Metabolism is Modulated by Synovial Fluid Through Metalloproteinase Activity.

Sun EY, Fleck AKM, Abu-Hakmeh AE, Kotsakis A, Leonard GR, Wan LQ.

Ann Biomed Eng. 2018 Jun;46(6):810-818. doi: 10.1007/s10439-018-2010-1. Epub 2018 Mar 27.

PMID:
29589167
23.

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.

Messaritakis I, Politaki E, Koinis F, Stoltidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulias V, Kotsakis A.

Sci Rep. 2018 Feb 2;8(1):2238. doi: 10.1038/s41598-018-20502-1.

24.

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.

Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A.

Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018.

25.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.

Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.

26.

Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups.

Messaritakis I, Kotsakis A, Georgoulias V.

J Thorac Dis. 2017 Dec;9(12):4817-4820. doi: 10.21037/jtd.2017.11.106. No abstract available.

27.

2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15-17, 2016, Athens, Greece.

Samara P, Kotsakis A, Tsitsilonis O, Georgoulias V, Pawelec G, Baxevanis CN.

Cancer Immunol Immunother. 2018 Jan;67(1):153-159. doi: 10.1007/s00262-017-2096-6. Epub 2017 Dec 1.

PMID:
29196790
28.

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.

Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulias V.

PLoS One. 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. eCollection 2017.

29.

Errors During Resuscitation: The Impact of Perceived Authority on Delivery of Care.

Delaloye NJ, Tobler K, OʼNeill T, Kotsakis A, Cooper J, Bank I, Gilfoyle E; Teams4Kids Investigators and the Canadian Critical Care Trials Group.

J Patient Saf. 2017 Jun 30. doi: 10.1097/PTS.0000000000000359. [Epub ahead of print]

PMID:
28671912
30.

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.

Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2018 Feb;20(2):140-149. doi: 10.1007/s12094-017-1702-6. Epub 2017 Jun 19.

PMID:
28631135
31.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

PMID:
28523597
32.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A.

Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.

33.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
34.

Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types.

Kotsakis A, Georgoulias V.

Lancet Oncol. 2017 May;18(5):556-557. doi: 10.1016/S1470-2045(17)30227-9. Epub 2017 Mar 31. No abstract available. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433.

PMID:
28373006
35.

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).

Messaritakis I, Stoltidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, Souglakos J, Georgoulias V.

Sci Rep. 2017 Mar 28;7:45351. doi: 10.1038/srep45351.

36.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A.

Lung Cancer. 2017 Feb;104:16-23. doi: 10.1016/j.lungcan.2016.12.008. Epub 2016 Dec 14.

PMID:
28212995
37.

Improved Clinical Performance and Teamwork of Pediatric Interprofessional Resuscitation Teams With a Simulation-Based Educational Intervention.

Gilfoyle E, Koot DA, Annear JC, Bhanji F, Cheng A, Duff JP, Grant VJ, St George-Hyslop CE, Delaloye NJ, Kotsakis A, McCoy CD, Ramsay CE, Weiss MJ, Gottesman RD; Teams4Kids Investigators and the Canadian Critical Care Trials Group.

Pediatr Crit Care Med. 2017 Feb;18(2):e62-e69. doi: 10.1097/PCC.0000000000001025.

PMID:
28157808
38.

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.

Matikas A, Mistriotis D, Georgoulias V, Kotsakis A.

Crit Rev Oncol Hematol. 2017 Feb;110:1-12. doi: 10.1016/j.critrevonc.2016.12.005. Epub 2016 Dec 9. Review.

PMID:
28109399
39.

Classifying circulating tumor cells to monitor cancer progression.

Economopoulou P, Georgoulias V, Kotsakis A.

Expert Rev Mol Diagn. 2017 Feb;17(2):153-165. doi: 10.1080/14737159.2017.1275572. Epub 2016 Dec 29. Review.

PMID:
28032524
40.

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.

Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK.

Sci Rep. 2016 Dec 15;6:39247. doi: 10.1038/srep39247.

41.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V.

Clin Lung Cancer. 2016 Nov;17(6):543-549. doi: 10.1016/j.cllc.2016.05.009. Epub 2016 Jun 2.

PMID:
27397849
42.

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

Matikas A, Kentepozidis N, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2016 Nov;17(6):474-482. doi: 10.1016/j.cllc.2016.05.006. Epub 2016 Jun 2. Review.

PMID:
27341790
43.

The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.

Matikas A, Georgoulias V, Kotsakis A.

Expert Rev Respir Med. 2016 Nov;10(11):1229-1241. doi: 10.1080/17476348.2016.1240620. Epub 2016 Oct 3.

PMID:
27661451
44.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.

Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2016 Sep 27;115(7):784-8. doi: 10.1038/bjc.2016.281. Epub 2016 Sep 8.

45.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.

PMID:
27492015
46.

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).

Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group.

Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22.

PMID:
27335027
47.

Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.

Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V.

J Geriatr Oncol. 2017 Jan;8(1):23-30. doi: 10.1016/j.jgo.2016.05.002. Epub 2016 Jun 2.

PMID:
27264267
48.

Description of PICU Unplanned Readmission.

Kotsakis A, Stevens D, Frndova H, Neal R, Williamson G, Mohseni-Bod H, Parshuram CS.

Pediatr Crit Care Med. 2016 Jun;17(6):558-62. doi: 10.1097/PCC.0000000000000735.

PMID:
27261644
49.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

50.

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer.

Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A.

J Thorac Oncol. 2016 Aug;11(8):1263-1272. doi: 10.1016/j.jtho.2016.04.026. Epub 2016 May 10.

Supplemental Content

Loading ...
Support Center